Can a daily shot of IL-2 tame chronic GVHD?
NCT ID NCT01366092
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This phase 2 trial tests whether daily low-dose injections of interleukin-2 (IL-2) can help control chronic graft-versus-host disease (cGVHD) in 35 people who did not respond to steroids. cGVHD is a complication after a stem cell transplant where the donor's immune cells attack the recipient's body. The study aims to see if IL-2 can reduce cGVHD symptoms and allow patients to lower their steroid use.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
Active substance
Interleukin-2 (IL-2)
What this could lead to
If it works, this could offer a new way to control chronic GVHD without high-dose steroids, potentially improving quality of life for transplant recipients.
What could go wrong
This is a small, early-phase trial with only 35 participants. The treatment may not work for everyone, and side effects from IL-2 are possible. Results need confirmation in larger studies.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for CHRONIC GRAFT-VERSUS-HOST-DISEASE are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Beth Israel Deaconess Medical Center
Boston, Massachusetts, 02215, United States
-
Dana-Farber Cancer Institute
Boston, Massachusetts, 02214, United States
-
Massachusetts General Hospital
Boston, Massachusetts, 02214, United States